Neurocrine officer sells 826 shares at $157

Neurocrine Biosciences’ Chief Corp. Affairs Officer reported PRSU vesting, tax withholding, and a small Rule 10b5-1 plan sale of common stock.

Rhea-AI Filing Summary

Neurocrine Biosciences, Inc. (NBIX) reported insider equity activity by Chief Corp. Affairs Officer David W. Boyer. On September 11, 2026, 3,587 shares of common stock were acquired at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified. On the same date, 1,936 shares were withheld by the company to satisfy tax withholding requirements on the PRSU vesting, and no shares were sold in that transaction. On September 14, 2026, 826 shares were sold in the open market at a weighted average price of $157.4462 per share under a Rule 10b5-1 trading plan adopted on February 23, 2026.

Insider Trade Summary 10b5-1

Net Seller: 826 shares

Net Sell 3 txns

Insider Boyer David W.

Role Chief Corp. Affairs Officer

Sold 826 shs ($130K)

Type	Security	Shares	Price	Value
Sale	Common Stock F4, F5	826	$157.4462	$130K
Grant/Award	Common Stock F1, F2	3,587	$0.00	$0.00
Tax Withholding	Common Stock F3	1,936	$156.22	$302K

Holdings After Transaction: Common Stock — 8,722 shares (Direct)

Footnotes (5)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
3. F3. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
4. F4. The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
5. F5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Key Figures

Shares sold: 826 shares Sale price (weighted average): $157.4462 per share Shares acquired from PRSU vesting: 3,587 shares +3 more

6 metrics

Shares sold 826 shares Common stock sale on September 14, 2026

Sale price (weighted average) $157.4462 per share 826-share sale in multiple transactions between $157.31 and $157.5950

Shares acquired from PRSU vesting 3,587 shares Common stock acquired at $0.00 per share on September 11, 2026

Shares withheld for taxes 1,936 shares Shares withheld on September 11, 2026 to satisfy tax withholding on PRSU vesting

Tax-withholding price reference $156.22 per share Value used for 1,936 shares withheld to cover tax liability

10b5-1 plan adoption date February 23, 2026 Trading plan governing the 826-share sale on September 14, 2026

Key Terms

performance restricted stock units (PRSUs), Rule 10b5-1 trading plan, weighted average sales price per share, tax withholding requirements

4 terms

performance restricted stock units (PRSUs) financial

"The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest"

Rule 10b5-1 trading plan regulatory

"effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price per share financial

"Represents a weighted average sales price per share. These shares were sold in multiple"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements on vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NBIX report for David W. Boyer on this Form 4?

The filing reports 3,587 shares of Neurocrine Biosciences common stock acquired from PRSU vesting on September 11, 2026, 1,936 shares withheld to cover related taxes, and a sale of 826 shares on September 14, 2026 under a Rule 10b5-1 trading plan.

How many NBIX shares did the officer sell and at what price?

On September 14, 2026, the officer sold 826 shares of Neurocrine Biosciences common stock at a weighted average price of $157.4462 per share, in multiple transactions ranging from $157.31 to $157.5950, executed under a Rule 10b5-1 trading plan.

What PRSU-related share vesting did NBIX disclose for David W. Boyer?

The company disclosed that 3,587 shares of common stock were acquired on September 11, 2026 upon vesting of previously granted performance restricted stock units (PRSUs), after achievement of one performance metric was certified on that date.

Were NBIX shares sold to cover taxes on the PRSU vesting?

No. The filing states that 1,936 shares were withheld by Neurocrine Biosciences on September 11, 2026 to satisfy tax withholding requirements on PRSU vesting, and explicitly notes that no shares were sold in that tax-withholding transaction.

Was the NBIX share sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 notes that the 826-share sale on September 14, 2026 was conducted by a broker pursuant to instructions in a Rule 10b5-1 trading plan adopted by the reporting person on February 23, 2026, and issuer policy restricts amending such plans after adoption.

Did the officer pay anything for the NBIX shares received from PRSU vesting?

No purchase price was paid. The Form 4 reports the 3,587 shares acquired on September 11, 2026 from PRSU vesting at a price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:04 PM Accepted by SEC EDGAR 09/15/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyer David W.

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp. Affairs Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		3,587	A	$0	11,484(2)	D
Common Stock	09/11/2026		F(3)		1,936	D	$156.22	9,548	D
Common Stock	09/14/2026		S(4)		826	D	$157.4462(5)	8,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Includes an aggregate of 98 shares purchased on August 31, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

3. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

4. The disposition reported on this line was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

5. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $157.31 to $157.5950. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)